ALMRHealthcare · Medical Devices

ALMR Stock Forecast: Alamar Biosciences, Inc. (California) Price Predictions for 2026-2027

Last close, 14 Aug 2026

$33

+0.73% on the day

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) hold a median 12-month price target of $34 — +2.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 14 Aug 2026 — in the weakest quartile.

Market cap

$2.3B

Ticker Nerd rank

4 / 100

Median analyst target

$34

Analysts covering

Total return, dividends reinvested

+16.5%

+22.6%

From high

−9.3%

From low

+73.7%

$19

$37

Range since 17 Apr 2026, adjusted closes · the dot is the last close

Ticker Nerd rank

ALMR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Alamar Biosciences, Inc. (California) on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Aug 2026

4 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions

Size

Momentum

Value

Growth

Accruals

Quality

Issuance

Volatility

Revisions (83): Analysts have, on balance, been raising their forecasts.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ALMR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ALMR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 17 Apr 2026Adjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says5 analysts

4 Buy1 Hold0 Sell

Low $31Median $34High $35

The green dot is the last close — the median target sits +2.5% from it.

Recent analyst actionsNewest first

Date	Firm	Action	Rating	Target
11 Aug 2026	JP Morgan	Maintains	Overweight	$32 → $35
11 Aug 2026	Stifel	Maintains	Buy	$28 → $32
12 May 2026	JP Morgan	Initiates	Overweight	—
12 May 2026	JP Morgan	Initiates	Overweight	$30
12 May 2026	Leerink Partners	Initiates	Outperform	—
12 May 2026	Leerink Partners	Initiates	Outperform	$35
12 May 2026	Stifel	Initiates	Buy	—
12 May 2026	Stifel	Initiates	Buy	$28
12 May 2026	TD Cowen	Initiates	Buy	—
12 May 2026	TD Cowen	Initiates	Buy	$30

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ALMR appears on the weeks it earns a place.

Estimates

ALMR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year

Analysts raising

Analysts cutting

Fundamentals

Alamar Biosciences, Inc. (California) (ALMR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −74.0×
Price / sales: 22.9×
Price / book: −12.1×
EV / EBITDA: −56.1×

Growth & margins

Revenue growth (YoY): 82.1%
Earnings growth (YoY): —
Gross margin: 55.5%
Operating margin: −46.0%
Net margin: −49.5%

Returns & dividend

Return on equity: 18.8%
Return on assets: −21.3%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

ALMR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Devices

Company	Market cap	TKN rank
ALMRAlamar Biosciences, Inc. (California)	$2.3B	4
ESTAEstablishment Labs Holdings, Inc.	$2.3B	77
BFLYButterfly Network, Inc.	$2.4B	72
UFPTUFP Technologies, Inc.	$2.5B	73
NEOGNeogen Corp.	$2.5B	96
AXGNAxoGen, Inc.	$2.6B	78
NVCRNovoCure Ltd.	$2.0B	94

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Alamar Biosciences, Inc. (California) — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ALMR news & analysis

Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument

Seeking Alpha · 14 Aug 2026positive

Alamar Biosciences reported Q2 2026 revenue of $29.4M, up 82% year-over-year, with consumables sales up 147% and gross margin rising to 60%. The article highlights the company's content-driven proteomics platform, expanding biomarker panels, installed base, and recurring revenue opportunities as drivers of long-term growth.

Why it matters — ALMR watchers would care because the item highlights accelerating consumables revenue, improving gross margins, and recurring revenue potential from its installed base, which are key indicators of the company's growth trajectory and revenue quality.

Alamar Biosciences Stock Soars, CEO Says Company Is Well-Positioned to Sustain Upcoming Momentum

Benzinga · 11 Aug 2026positive

Alamar Biosciences shares are trading higher after the company announced it is expanding its global partnership with the Alzheimer's Disease Data Initiative and Gates Ventures. CEO comments that the company is well-positioned to sustain its upcoming momentum.

Why it matters — Alamar Biosciences watchers would care because the expanded partnership with major Alzheimer's-focused organizations signals strengthened strategic collaborations that could support the company's future trajectory.

Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings Call Transcript

Seeking Alpha · 10 Aug 2026neutral

Alamar Biosciences, Inc. (ALMR) held its Q2 2026 earnings call, and a transcript of the call was published on Seeking Alpha. The item reports the availability of the earnings call transcript.

Why it matters — ALMR watchers would want to review the transcript to hear management's discussion of the company's Q2 2026 performance and outlook directly from its executives.

Alamar Biosciences Q2 Earnings Call Highlights

MarketBeat · 10 Aug 2026positive

Alamar Biosciences reported second-quarter 2026 revenue of $29.4 million, an 82% increase year over year, driven by growth in consumables, instrument placements and service revenue. The earnings call was the company's first since completing its April initial public offering.

Why it matters — The strong revenue growth and first post-IPO earnings call provide an early look at Alamar's financial trajectory as a newly public company.

Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome

GlobeNewsWire · 28 July 2026positive

Alamar Biosciences launched the NULISAseq™ Immune 340 Panel, an expanded panel designed for comprehensive profiling of the immune proteome in translational and clinical research.

Why it matters — ALMR watchers would care because the new panel could strengthen the company's position in the immunoproteomics market, with potential applications across cancer, cardiovascular, metabolic, autoimmune, and aging research.

FAQ

Frequently asked questions about ALMR stock

What is the ALMR stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Alamar Biosciences, Inc. (California) have a median 12-month price target of $34, with estimates ranging from $31 to $35. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ALMR stock a buy right now?

Of the 5 analysts covering Alamar Biosciences, Inc. (California), 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Alamar Biosciences, Inc. (California) 4 out of 100 across roughly 4,600 US stocks as at 14 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ALMR?

As at 14 Aug 2026, Alamar Biosciences, Inc. (California) ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (83 of 100).

Will ALMR stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +2.5% from the last close, and Ticker Nerd's factor model ranks Alamar Biosciences, Inc. (California) 4 out of 100 as at 14 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ALMR stock forecast for 2030?

No analyst covering Alamar Biosciences, Inc. (California) publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ALMR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $31 to $35 over the next 12 months.

What does Alamar Biosciences, Inc. (California) do?

Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies.

What is the latest news on ALMR?

The most recent item we track (Seeking Alpha, 14 Aug 2026): "Alamar Biosciences: The Content Flywheel Is More Valuable Than The Instrument". Alamar Biosciences reported Q2 2026 revenue of $29.4M, up 82% year-over-year, with consumables sales up 147% and gross margin rising to 60%. The article highlights the company's content-driven proteomics platform, expanding biomarker panels, installed base, and recurring revenue opportunities as drivers of long-term growth.

Company

About Alamar Biosciences, Inc. (California).

Alamar Biosciences, Inc. is a commercial-stage proteomics company specializing in advanced protein detection and analysis technologies. It develops and commercializes the proprietary NULISA platform, designed to overcome limitations of traditional proteomics tools by enabling detection of protein biomarkers at extremely low concentrations in non-invasive biological fluids like blood. Key features include ultra-high sensitivity, high specificity, flexible multiplexing capabilities, broad dynamic range, and seamless automation, establishing a gold standard for precision proteomics. The company serves the healthcare sector, particularly the medical devices industry, by providing tools for disease detection research, including early identification of cancer and other diseases through protein biomarker platforms. Alamar Biosciences, Inc. focuses on powering precision medicine applications in research and diagnostics. Founded in 2018 and headquartered in Fremont, California, it plays a significant role in advancing proteomics for biological and clinical research.

CEO Dr. Yuling Luo Ph.D. · 286 employees · United States · https://alamarbio.com